SITC Guidelines News

Manuscript Title:

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0

Draft Manuscript Summary

The Society for Immunotherapy of Cancer (SITC) Renal Cell Carcinoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma,” an update to the society’s 2019 CPG for this disease setting.

The new RCC manuscript is part of the broader SITC Cancer Immunotherapy Guidelines program that has produced a collection of CPGs. These guidelines are developed by multi-disciplinary panels of experts who draw from their own practical experience, as well as evidence in the published literature and clinical trial data, to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer. You may read the entire series of CPGs in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal.

Instructions for Requesting Draft Manuscript

During SITC’s open comment period, key stakeholders and other experts in the field may critically review a confidential copy of the CPG draft and provide input prior to its publication. All participants must complete and sign a non-disclosure and confidentiality agreement prior to obtaining the draft manuscript. All comments must be received by the noted deadline to be considered.

For more information on requesting the draft manuscript, please visit: sitcancer.org/CPGComment

Deadlines:

• Non-disclosure and Confidentiality Agreement must be submitted to SITC by Wednesday May 7, 2025.
• Comments on the draft manuscript must be submitted on or before Thursday May 8, 2025 at 11:59 p.m. to be considered.